Stockchase Opinions

Robert Floyd Isotechnnika Inc ISA-T WEAK BUY Jan 07, 2005

Their particular area of expertise is getting involved with drugs that are involved with transplants that reduce rejection. Outlook for the company is quite interesting. In phase 2 and 3 trials so they still have a ways to go. Speculative.
$2.180

Stock price when the opinion was issued

biotechnology pharmaceutical
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

BUY
Prefers over Biomira.
BUY
Strong joint venture. Should move up as the clinical trials go through.
BUY
Has been able to meet ,ilestones.
BUY
An interesting little company. Good cash position. Strong management.
BUY
Solid growth company. Well along in clinical trials. Well run and the upside is pretty good. Some good partnerships. Good product. If you want a Cdn biotech, this is a good one.
BUY
Thinks the stock should move up from this level. Have a good opportunity to bring their product to market. Should rally by the middle of 2004.
BUY
Has a better product than cyclosporine. This should create a great marketplace for them. With more results coming out in 2004, you should see the stock move-up quite nicely.
DON'T BUY
Drug development. Burning up cash hand over fist. In sloppy markets you have to watch out. There's no earnings or fundamental support. Very early stages in drug development and will have to raise money, so will dilute shareholders.
DON'T BUY
Nothing fundamentally horrible about this company but it does have a small market cap, which is an out-of-favour sector. Small cap biotech sector is not a place to be.